Pentose Phosphate Pathway

Glucose has two destinies

When a molecule of glucose enters a cell and gets phosphorylated to glucose-6-phosphate, it stands at a fork. Most of it usually flows down glycolysis, splitting into pyruvate and harvesting ATP. But a fraction is diverted into the pentose phosphate pathway — a parallel route that makes no ATP at all. Why would a cell deliberately spend glucose without getting energy back? Because there are two molecules that the energy-extracting pathways cannot supply, and that every cell needs in bulk: NADPH and ribose-5-phosphate.

NADPH is reducing power — a loaded electron carrier used to build molecules (fatty acids, cholesterol, deoxyribonucleotides) and to defend against oxidative damage. Ribose-5-phosphate is the five-carbon sugar that becomes the structural backbone of DNA, RNA, ATP, NAD⁺, FAD, and coenzyme A. The pentose phosphate pathway is the cell's dedicated factory for both. It is sometimes called the hexose monophosphate shunt or phosphogluconate pathway, and it runs in the cytosol alongside glycolysis, drawing from the same glucose-6-phosphate pool.

Phase one: the oxidative arm makes NADPH

The first phase is oxidative and effectively irreversible — it commits the carbon to the pathway. It runs three reactions:

• Glucose-6-phosphate dehydrogenase (G6PD) oxidizes glucose-6-phosphate to 6-phosphogluconolactone, reducing NADP⁺ to NADPH. This is the committed, rate-limiting step.
• Lactonase hydrolyzes the lactone ring to 6-phosphogluconate.
• 6-phosphogluconate dehydrogenase oxidatively decarboxylates 6-phosphogluconate, releasing one carbon as CO₂ and producing a second NADPH, leaving the five-carbon sugar ribulose-5-phosphate.

The bookkeeping for the oxidative arm, per glucose-6-phosphate:

Glucose-6-P + 2 NADP⁺ + H₂O → Ribulose-5-P + 2 NADPH + 2 H⁺ + CO₂

Two NADPH harvested, one carbon lost as carbon dioxide, and a pentose left over. No ATP made, none consumed. That CO₂ is the molecular signature distinguishing this oxidation from glycolysis — the pathway literally counts a six-carbon sugar down to a five-carbon one.

Phase two: the non-oxidative arm shuffles carbon

The second phase is non-oxidative and fully reversible. It makes no NADPH; instead it is a set of sugar-rearranging reactions that let the cell convert the five-carbon ribulose-5-phosphate into whatever it actually needs. An isomerase turns ribulose-5-phosphate into ribose-5-phosphate (the ring that goes into nucleotides), while an epimerase makes xylulose-5-phosphate.

Then two remarkable enzymes do carbon accounting. Transketolase (which uses thiamine pyrophosphate, vitamin B1, as a cofactor) transfers two-carbon units between sugars; transaldolase transfers three-carbon units. Working together they interconvert 3-, 4-, 5-, 6-, and 7-carbon sugars — including the unusual seven-carbon sedoheptulose-7-phosphate — until the carbon lands on molecules the cell wants. The classic net reaction converts three pentoses (15 carbons) into two fructose-6-phosphates and one glyceraldehyde-3-phosphate (15 carbons), feeding straight back into glycolysis:

3 Ribulose-5-P → 2 Fructose-6-P + Glyceraldehyde-3-P

Because this phase is reversible, the same enzymes can run backward: a cell that needs ribose but not NADPH can pull glycolytic fructose-6-phosphate and glyceraldehyde-3-phosphate into ribose-5-phosphate without ever touching the oxidative arm. This reversibility is what gives the pathway its flexibility.

Four ways to run the same machine

Because the oxidative and non-oxidative arms can be coupled in different ratios, the pentose phosphate pathway runs in four different modes depending on what the cell needs more — NADPH, ribose, both, or NADPH plus energy. This adaptability is the whole point.

Cellular need	How the pathway runs	Example tissue
Ribose only (lots of nucleotides, little NADPH)	Non-oxidative arm in reverse; glycolytic intermediates → ribose-5-P	Skeletal muscle
Balanced ribose + NADPH	Oxidative arm produces both NADPH and ribose-5-P directly	Dividing cells, bone marrow
NADPH only (no ribose needed)	Oxidative arm runs; ribose recycled to fructose-6-P, back through pathway	Adipose tissue, lactating mammary gland
NADPH + ATP	Excess fructose-6-P and G3P enter glycolysis for energy	Liver under high biosynthetic load

NADPH vs NADH: one phosphate, two economies

NADPH and NADH look almost identical — they differ by a single phosphate group hanging off the adenine ribose. Yet cells keep them as two entirely separate currencies, with enzymes evolved to recognize the phosphate and pick the right one. The distinction is functional, not chemical accident.

Property	NADH	NADPH
Main source	Glycolysis, Krebs cycle	Pentose phosphate pathway (oxidative arm)
Main role	Catabolism — carry electrons to make ATP	Anabolism — carry electrons to build molecules
Typical cellular ratio	NAD⁺/NADH high (~700:1) — mostly oxidized	NADP⁺/NADPH low (~0.01:1) — mostly reduced
Destination	Electron transport chain	Fatty-acid & cholesterol synthesis, glutathione reduction

Keeping the NADPH pool heavily reduced is precisely what makes it a good biosynthetic and antioxidant reservoir — it is always "charged" and ready to donate electrons. The pentose phosphate pathway exists largely to keep it that way.

NADPH and the glutathione shield

Beyond construction, NADPH runs the cell's main chemical defense against oxidative stress. Reactive oxygen species — hydrogen peroxide, superoxide — constantly threaten to damage membranes, proteins, and DNA. The enzyme glutathione peroxidase neutralizes peroxide using reduced glutathione (GSH), which gets oxidized to GSSG in the process. To recycle GSSG back to GSH, glutathione reductase needs NADPH. No NADPH, no regenerated glutathione, no defense.

This is why red blood cells are so dependent on the pathway. Erythrocytes have no mitochondria and no nucleus, so the oxidative pentose phosphate pathway is their only source of NADPH — and they are full of oxygen, the very thing that generates oxidative stress. A red cell that cannot make NADPH cannot protect its hemoglobin and membranes, and it lyses.

G6PD deficiency: evolution's bargain with malaria

Glucose-6-phosphate dehydrogenase deficiency is the most common enzyme deficiency in humans, affecting an estimated 400 million people worldwide, concentrated in Africa, the Mediterranean, the Middle East, and Southeast Asia. People with low G6PD activity get by normally most of the time, but an oxidative challenge overwhelms their thin NADPH supply and their red cells hemolyze. Triggers include fava beans (hence the historical name "favism"), certain antimalarials (primaquine), some sulfa antibiotics, and ordinary infections.

The puzzle is why such a "bad" allele is so common. The answer is balancing selection: the malaria parasite Plasmodium depends on the oxidative environment of the red cell, and G6PD-deficient cells are a hostile, oxidant-stressed habitat. Carriers gain partial protection against severe malaria, so in malaria-endemic regions the deficiency allele was favored despite its costs — the same evolutionary logic that maintains the sickle-cell trait. The geographic overlap of G6PD deficiency with historical malaria is one of the clearest fingerprints of natural selection on the human genome.

Regulation: flux follows NADPH demand

The pathway's flux is governed almost entirely at the committed step, G6PD, and the master signal is the NADP⁺/NADPH ratio. NADP⁺ is a substrate for G6PD; NADPH competes with it and inhibits the enzyme. So when a cell spends NADPH — on a burst of fatty-acid synthesis, or quenching an oxidative attack — NADP⁺ accumulates and G6PD speeds up to refill the pool. When NADPH is abundant, the enzyme idles. The pathway therefore acts like a demand-driven valve, opening exactly as fast as the cell consumes reducing power.

Tissue distribution mirrors demand. The pathway is highly active in tissues with heavy biosynthetic or antioxidant load: liver and adipose (fatty-acid synthesis), adrenal cortex and gonads (steroid synthesis), lactating mammary gland, and red blood cells. Skeletal muscle, which does little fatty-acid synthesis, has very low oxidative-arm activity and uses mainly the reversible non-oxidative arm to scrape together ribose when it needs nucleotides.

Why it matters beyond the textbook

• Cancer. Rapidly proliferating tumor cells upregulate the pathway to supply ribose for DNA replication and NADPH for both lipid synthesis and antioxidant survival; it is an active drug target.
• Photosynthesis. The Calvin cycle's regeneration phase reuses several of the same sugar-shuffling reactions (transketolase, the pentose interconversions) in reverse — the chemistry is deeply conserved across life.
• Aging and redox biology. Declining NADPH supply weakens antioxidant defense, linking the pathway to oxidative damage over a lifetime.
• Pharmacology. Drug toxicity in G6PD-deficient patients is a routine clinical screening concern before prescribing oxidant medications.